A detailed history of American Portfolios Advisors transactions in Novavax Inc stock. As of the latest transaction made, American Portfolios Advisors holds 848 shares of NVAX stock, worth $7,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares
848
Holding current value
$7,216
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$18.2 - $76.12 $15,433 - $64,549
848 New
848 $15.4 Million
Q2 2022

Mar 20, 2023

SELL
$36.28 - $75.29 $7,110 - $14,756
-196 Reduced 23.11%
652 $33.5 Million
Q1 2022

Mar 21, 2023

SELL
$69.73 - $142.9 $13,667 - $28,008
-196 Reduced 23.11%
652 $48 Million
Q4 2021

Mar 21, 2023

SELL
$134.56 - $217.97 $33,909 - $54,928
-252 Reduced 29.72%
596 $85.3 Million
Q3 2021

Mar 22, 2023

SELL
$177.8 - $270.58 $42,316 - $64,398
-238 Reduced 28.07%
610 $126 Million
Q2 2021

Mar 22, 2023

SELL
$121.0 - $257.67 $79,376 - $169,031
-656 Reduced 77.36%
192 $40.8 Million
Q1 2021

Mar 22, 2023

SELL
$112.98 - $319.93 $70,273 - $198,996
-622 Reduced 73.35%
226 $41 Million
Q4 2020

Mar 22, 2023

BUY
$78.74 - $139.5 $194,487 - $344,565
2,470 Added 291.27%
3,318 $370 Million
Q3 2020

Mar 22, 2023

SELL
$79.44 - $178.51 $17,715 - $39,807
-223 Reduced 26.3%
625 $67.7 Million
Q2 2020

Mar 24, 2023

BUY
$13.86 - $83.61 $2,772 - $16,722
200 Added 27.32%
932 $77.7 Million
Q1 2020

Mar 24, 2023

SELL
$3.93 - $16.0 $455 - $1,856
-116 Reduced 13.68%
732 $9.94 Million
Q4 2019

Mar 24, 2023

SELL
$3.69 - $5.22 $2,575 - $3,643
-698 Reduced 82.31%
150 $597,000
Q2 2019

Mar 24, 2023

SELL
$4.93 - $12.2 $3,441 - $8,515
-698 Reduced 82.31%
150 $879,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $666M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.